改善HCC治疗:创新地将HDAC2抑制剂与PD-1/PD-L1抑制剂结合起来
Rui Han1,2,3,4,5,6, Changquan Ling7,8, Yuqian Wang7,8
1Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, P. R. China. dianxiqiao@foxmail.com.
Cancer cell international
|September 16, 2023
概括
这项研究探讨了将基因组脱乙酶2抑制剂与免疫检查点抑制剂结合起来,用于肝细胞癌治疗. 这种新的方法可能会改善HCC患者的抗癌免疫力和治疗疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 具有高死亡率,有效治疗方法有限.
- 免疫检查点抑制剂 (ICI) 是有前途的,但对HCC患者的一个小组有益.
- 基因组脱乙酶2 (HDAC2) 抑制剂在其他癌症中有效,但对于HCC尚未确立.
研究的目的:
- 研究将HDAC2抑制剂与ICI结合用于增强HCC治疗的潜力.
- 探索HDAC2抑制如何调节PD-L1乙化和抗瘤免疫.
- 突出瓦莱特酸 (VA) 作为一种新的HDAC2抑制剂用于HCC治疗.
主要方法:
- 对癌症治疗中的HDAC2抑制剂和ICI现有文献的综述.
- 对PD-L1调节中的HDAC2抑制机制的分析.
- 讨论临床前发现和结合疗法的未来研究方向.
主要成果:
- 抑制HDAC2可以调节PD-L1乙化,提高ICI的疗效.
- 瓦莱特酸 (VA) 是一种新型HDAC2抑制剂,在HCC中显示出单一治疗的潜力.
- 结合HDAC2抑制剂和ICI,为HCC提供了一个有前途的治疗策略.
结论:
- 将HDAC2抑制剂与ICI结合起来,为HCC治疗提供了一种新且有价值的策略.
- 需要进一步的研究来探索这种组合治疗的临床应用.
- 向HDAC2可以显著改善抗癌免疫力和HCC的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


